Postoperative Gabapentinoid Use Is Associated with Improved Survival in Glioblastoma: A Nationwide Population-Based Study

Clicks: 2
ID: 317505
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Steady

Ranked #79 of 105 articles by views in Neuro-Oncology Advances

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Background Glioblastoma (GBM) is a highly aggressive primary brain tumor that can integrate into neural circuits implicated in tumor progression and treatment resistance. Gabapentinoids are proposed to disrupt such interactions. We analyzed postoperative gabapentinoid use and overall survival (OS) in nationwide adult GBM cohort. Methods This retrospective population-based study utilized the Turkish national healthcare registry, identifying adult patients with pathology-confirmed GBM who underwent surgery between 2016 and 2024. The primary endpoint was OS. Stabilized inverse probability of treatment weighting (sIPTW) was applied to adjust for potential confounders, and survival associations were evaluated using multivariable Cox proportional hazards models. Survival curves were analyzed using Kaplan–Meier estimator, and statistical significance was defined as two-sided p-value <0.05. Results Of 11,924 patients, 701 (5.9%) utilized postoperative gabapentinoids. In sIPTW-weighted analyses, gabapentinoid utilization was associated with reduced mortality risk (HR 0.75; 95% CI, 0.66-0.84; p < 0.001). Age-stratified analyses demonstrated effect modification, with survival benefit observed in patients aged ≥55 years (HR 0.70; 95% CI, 0.60-0.81) but not in those <55 years. Within older subgroup, both gabapentin (n = 349; HR 0.70; 95% CI, 0.59-0.83; p < 0.001) and pregabalin (n = 248; HR 0.68; 95% CI, 0.56-0.83; p < 0.001) independently improved OS. Dose-response analyses suggested lower-mortality exposure ranges (gabapentin: 1,200-2,400 mg/day; pregabalin: >400 mg/day). Conclusions In this nationwide cohort, postoperative gabapentinoid use was associated with improved survival in patients with GBM, particularly aged ≥55 years. These findings support targeting neuron-glioma axis and warrant prospective evaluation of gabapentinoids as adjuvant therapies in GBM.
Reference Key
openalex_W7164930203 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Sahin Hanalioglu, Efecan Çekiç, Egemen Gok, Beyza Türken, Ayca Sahin, Sinem Bayram, Neslihan Ozturk, Naim Ata, Suayip Birinci, İlkay Işıkay, Elizabeth Claus, E Antonio Chiocca, Mutlu Hayran, Joshua D. Bernstock
Journal Neuro-Oncology Advances
Year 2026
DOI
10.1093/noajnl/vdag162
URL
https://doi.org/10.1093/noajnl/vdag162
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.